trial · primary record
Amivantamab and Recombinant Human Hyaluronidase
Locally Recurrent Skin Squamous Cell Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 86 |
| Primary completion | 2029-02-28 |
| Primary endpoint | Incidence of toxicity of interest (cohort A) |
| Registry ID | NCT07042295 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:45:21.889Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07042295
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.